A Phase 2 interventional study of ADT and OPC-34712 in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-06.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 5th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,036 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2009, is one of 7 in phase 2, and was the 21st registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
Drug: ADT · Drug: OPC-34712
Participants With Adverse Events (AEs).
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug-related by the physician. The severity was assessed as mild, moderate, or severe. A treament-emergent AE (TEAE) was defined as any AE that started after start of open-label brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study drug.
Time frame: After the Informed Consent Form (ICF) was signed, through Follow up 30 (+2) days after last visit
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score.
The CGI-S is a 7-point scale from 1 through 7. The items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing.
Time frame: Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and 52 (last-observation-carried-forward [LOCF])
Mean Clinical Global Impression - Improvement (CGI-I) Scale Score.
The items on CGI-I scale are 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) was set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI improvement was compared to the participants condition at Baseline.
Time frame: Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and 52 (LOCF)
1036 participants entered trial, including 792 who had rolled over from previous studies and 244 de novo participants. Of the 792 rollovers, 337 were 6-week enrollers and the 52-week enrollers consisted of 699 enrolled participants (455 rollover and 244 de novo). This was a single arm study and all participants received the same treatment.
| Milestone | Brexpiprazole +ADT |
|---|---|
| Started | 1036 |
| Completed | 560 |
| Not completed | 476 |
| Withdrew: Lost to follow-up | 52 |
| Withdrew: Adverse event | 127 |
| Withdrew: Participant met withdrawal criteria | 40 |
| Withdrew: Withdrawal by subject | 100 |
| Withdrew: Protocol deviation | 83 |
| Withdrew: Lack of efficacy | 68 |
| Withdrew: Physician decision | 6 |
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug-related by the physician. The severity was assessed as mild, moderate, or severe. A treament-emergent AE (TEAE) was defined as any AE that started after start of open-label brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study drug.
| Participants | Brexpiprazole+ADT |
|---|---|
| Participants with TEAEs | 851 |
| Participants with serious TEAEs | 30 |
The CGI-S is a 7-point scale from 1 through 7. The items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing.
| Units on a scale | Brexpiprazole+ADT |
|---|---|
| Week 1 | -0.09 ± 0.60 |
| Week 2 | -0.35 ± 0.82 |
| Week 4 | -0.63 ± 0.96 |
| Week 6 | -0.79 ± 1.03 |
| Week 8 | -0.92 ± 1.12 |
| Week 14 | -0.93 ± 1.14 |
| Week 20 | -1.08 ± 1.17 |
| Week 26 | -1.13 ± 1.24 |
| Week 32 | -1.24 ± 1.24 |
| Week 38 | -1.37 ± 1.28 |
| Week 44 | -1.46 ± 1.27 |
| Week 52 | -1.52 ± 1.34 |
| Week 52-LOCF | -0.81 ± 1.24 |
The items on CGI-I scale are 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) was set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI improvement was compared to the participants condition at Baseline.
| Units on a scale | Brexpiprazole+ADT |
|---|---|
| Week 1 | 3.38 ± 0.94 |
| Week 2 | 3.04 ± 1.06 |
| Week 4 | 2.67 ± 1.09 |
| Week 6 | 2.46 ± 1.10 |
| Week 8 | 2.36 ± 1.10 |
| Week 14 | 2.36 ± 1.23 |
| Week 20 | 2.22 ± 1.17 |
| Week 26 | 2.16 ± 1.12 |
| Week 32 | 2.08 ± 1.13 |
| Week 38 | 1.97 ± 1.11 |
| Week 44 | 1.91 ± 1.14 |
| Week 52 | 1.92 ± 1.15 |
| Week 52-LOCF | 2.57 ± 1.31 |
Collected over After the ICF was signed, through the treatment period and through Follow-up (telephone contact or in-clinic visit) 30 (+ 2) days after the last visit.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole+ADT | — | 29/697 (4.2%) | 684/1,034 (66.2%) |
| Event | Brexpiprazole+ADT |
|---|---|
| DepressionPsychiatric disorders | 3/697 |
| Suicidal ideationPsychiatric disorders | 3/697 |
| Suicide attemptPsychiatric disorders | 3/697 |
| Intentional overdoseInjury, poisoning and procedural complications | 2/697 |
| AnxietyPsychiatric disorders | 2/697 |
| PancreatitisGastrointestinal disorders | 1/697 |
| Non-cardiac chest painGeneral disorders | 1/697 |
| CholecystitisHepatobiliary disorders | 1/697 |
| CholelithiasisHepatobiliary disorders | 1/697 |
| PneumoniaInfections and infestations | 1/697 |
| Event | Brexpiprazole+ADT |
|---|---|
| Weight increasedInvestigations | 217/1034 |
| AkathisiaNervous system disorders | 102/1034 |
| FatigueGeneral disorders | 95/1034 |
| SomnolenceNervous system disorders | 94/1034 |
| InsomniaPsychiatric disorders | 91/1034 |
| Increased appetiteMetabolism and nutrition disorders | 87/1034 |
| HeadacheNervous system disorders | 87/1034 |
| Upper respiratory tract infectionInfections and infestations | 67/1034 |
| AnxietyPsychiatric disorders | 67/1034 |
| DizzinessNervous system disorders | 60/1034 |
| Age, Continuous(Years) | Brexpiprazole+ADT |
|---|---|
| Mean | 44.0 ± 11.0 |
| Sex: Female, Male(Participants) | Brexpiprazole+ADT |
|---|---|
| Female | 702 |
| Male | 334 |
The record gives a start of Sep 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 2 years 11 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →